Saroja Pharma Industries India Limited — Others, 30-05-2025: Statement of deviation(s) or variation(s) under Reg. 32

Saroja Pharma Industries India Limited reports no deviation in the use of Rs. 9.11 Cr raised via IPO. Funds were mainly deployed as planned: Rs. 6.67 Cr for a manufacturing unit, Rs. 1.75 Cr to fully repay unsecured loans, and Rs. 0.31 Cr on IPO expenses. Around Rs. 0.38 Cr remains unutilized. The Audit Committee has reviewed and approved this use of proceeds, reflecting disciplined capital deployment aligned with the company’s business objectives and ensuring transparency for shareholders.